人胚肺成纖維細胞MRC-5

細胞名稱

人胚肺成纖維細胞MRC-5

貨物編碼

BFN6072012696

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

27℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途       2類

培養體系

DMEM高糖培養基+10%FBS+1%雙抗 

培養溫度

37℃

二氧化碳濃度

5%

簡介

人胚肺成纖維細胞MRC-5細胞系來自14周齡男性胎兒的正常肺組織，該細胞老化前能傳代42~46個倍增時間.

注釋

Group: Vaccine production cell line.

Biotechnology: Used for the production of the Human Diploid Cell Vaccine (HDCV) against rabies (Trade name: Imovax Rabies).

Biotechnology: Used for the production of the Hepatitis A vaccines Avaxim, Epaxal, Havrix and Vaqta.

Biotechnology: Used for the production of the live varicella virus vaccine (Trade name: Varivax).

Biotechnology: Used for the production of the live zoster vaccine (Trade name: Zostavax).

Characteristics: Senesces at 26 PDL (PubMed=17395773).

Doubling time: ~34 hours (lot 06022011), ~1.5 days (lot 05202005), ~2 days (lot 05192003), 36 hours (lot 041392), ~5 days (lot 031098), ~38 hours (lot 04212016) (JCRB).

Omics: DNA methylation analysis.

Omics: Proteome analysis by 2D-DE.

Omics: Proteome analysis by 2D-DE/MS.

Omics: Transcriptome analysis.

Misspelling: MCR-5; Occasionally.

Derived from sampling site: Fetal lung.

STR信息

Amelogenin        X,Y

CSF1PO        11,12

D2S1338        20

D3S1358        15,17

D5S818        11,12

D7S820        10,11

D8S1179        13

D13S317        11,14

D16S539        9,11

D18S51        15,21

D19S433        14,15

D21S11        31.2

FGA        21,23

Penta D        12

Penta E        12,16

TH01        8

TPOX        8

vWA        15

參考文獻

PubMed=10752125

Polianskaia G.G., Efremova T.N., Sakuta G.A.

The effect of mycoplasmal contamination of human embryonic lung cell line MRC-5 on the karyotypic variability.

Tsitologiia 42:190-195(2000)

PubMed=17395773; DOI=10.1634/stemcells.2006-0504

Sudo K., Kanno M., Miharada K., Ogawa S., Hiroyama T., Saijo K., Nakamura Y.

Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations.

Stem Cells 25:1610-1617(2007)

PubMed=19657000

Rubporn A., Srisomsap C., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Svasti J., Sangvanich P.

Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line.

Cancer Genomics Proteomics 6:229-237(2009)

PubMed=21637780; DOI=10.1371/journal.pgen.1002085

Nishino K., Toyoda M., Yamazaki-Inoue M., Fukawatase Y., Chikazawa E., Sakaguchi H., Akutsu H., Umezawa A.

DNA methylation dynamics in human induced pluripotent stem cells over time.

PLoS Genet. 7:E1002085-E1002085(2011)

PubMed=25903999; DOI=10.1002/biot.201400388

Genzel Y.

Designing cell lines for viral vaccine production: where do we stand?

Biotechnol. J. 10:728-740(2015)

CLPUB00391

Wadman M.

The vaccine race: science, politics, and the human costs of defeating disease.

(In) ISBN 9780525427537; pp.1-436; Viking; New York (2016)